Validating aurora b as an anticancer drug target

This leaves a vast space of the protein universe unexploited by cancer drugs.

Whether clinical resistance to these drugs can arise is unclear.As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effective against the abnormal proliferation of transformed cells.Moreover, these antimitotic drugs are also highly selective and sensitive.Despite the robust rate of discovery and the development of mitosis-selective inhibitors, the unpredictable complexities of the human body's response to these drugs still herald the biggest challenge towards clinical success.Undoubtedly, the need to bridge the gap between promising preclinical trials and effective translational bedside treatment prompts further investigations towards mapping out the mechanistic pathways of MCD, understanding how these drugs work as medicine in the body and more comprehensive target validations.

Validating aurora b as an anticancer drug target